Provention Bio, Inc.

PRVBNASDAQHealthcare

$24.98

+$0.00(+0.00%)

Market Cap$2.4B

P/E Ratio—

52W High$25.0

52W Low$3.185

Avg Volume2.8M

Open$24.99

Beta2.46

Free Cash Flow Financials Revenue

Provention Bio, Inc. (PRVB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PRVB · free cash flow · updated Jun 8, 2026

Core FCF metrics

PRVB · FCF · TTM · margin & CAGR

Free cash flow was −$76.2M for FY2022 (fiscal year ending 2022-12-31), up 20.9% year-over-year The FCF margin was -591.0%.

FY2022 Free Cash Flow−$76.2M▲ +20.9% YoY

Trailing 12M (TTM)−$76.2Mtrailing 4 quarters sum

FCF Margin-591.0%−$76.2M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PRVB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$75.4M(1M)−$76.2M▲ +20.9%-591.0%

FY2021−$95.4M(1M)−$96.3M▼ 24.4%—

FY2020−$76.3M(1M)−$77.4M▼ 114.7%—

FY2019−$36.1M(0M)−$36.1M▼ 59.3%—

FY2018−$22.6M(0M)−$22.6M▼ 363.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PRVB · P/FCF · FCF yield · FCF per share

Provention Bio, Inc. (PRVB) reported negative free cash flow of −$0.08B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

PRVB · cash flow statement · operating / investing / financing

For FY2022, Provention Bio, Inc. generated −$75.4M in operating cash flow and spent 1M in capital expenditures, yielding −$76.2M in free cash flow.

Operating Activities

−$75.4M

Cash from core business operations

2022-12-31

Investing Activities

−$88.1M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$129.4M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$75.4M) − |CapEx| (1M) = FCF (−$76.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PRVB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Provention Bio, Inc.YOU

PRVB

−$76.2M+20.9%-590.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Provention Bio, Inc. (PRVB) reported free cash flow of −$76.2M for FY2022 (fiscal year ending 2022-12-31), up 20.9% year-over-year. The FCF margin was -591.0%.

Provention Bio, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 6 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PRVB free cash flow · 8 questions

Provention Bio, Inc. free cash flow was −$76.2M for FY2022, up 20.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$76.2M.

PRVB free cash flowPRVB FCFPRVB FCF 2022PRVB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Provention Bio, Inc. · Provention Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026